Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

Suleiman Massarweh · Edward Romond · Esther P. Black ·
Emily Van Meter · Brent Shelton · Vera Kadamyan-Melkumian ·
Mark Stevens · Richard Elledge

Published online: 21 January 2015
© Springer Science+Business Media New York 2015

Erratum to: Breast Cancer Res Treat (2014)
143:325–332
DOI 10.1007/s10549-013-2810-9

In the original publication, one adverse event (renal failure-grade 3) was inadvertently omitted from the final adverse

event Table 3, when reconciling *related* vs. *all* adverse events on study. This event was reported during study conduct as unlikely related to study treatment, but should have been included in the final manuscript adverse events table.

The online version of the original article can be found under doi:[10.1007/s10549-013-2810-9](https://doi.org/10.1007/s10549-013-2810-9).

S. Massarweh · E. Romond
The Department of Internal Medicine, University of Kentucky,
Lexington, KY, USA

S. Massarweh (✉) · E. Romond · E. P. Black · E. Van Meter ·
B. Shelton · V. Kadamyan-Melkumian · M. Stevens
Markey Cancer Center, University of Kentucky, cc452,
800 Rose Street, Lexington, KY 40536, USA
e-mail: massarweh@uky.edu

R. Elledge
University of Health Sciences Center at San Antonio,
San Antonio, TX, USA

R. Elledge
Cancer Treatment and Research Center (CTRC), San Antonio,
TX, USA